Literature DB >> 27444026

The impact on the prognosis of unsuspected N2 disease in non-small-cell lung cancer: indications for thorough mediastinal staging in the modern era.

Ryosuke Tachi1, Aritoshi Hattori1, Takeshi Matsunaga1, Kazuya Takamochi1, Shiaki Oh1, Kenji Suzuki2.   

Abstract

PURPOSE: Predicting the prognosis of advanced non-small-cell lung cancer (NSCLC) patients who present with clinically unsuspected N2 is very different due to the heterogeneity of this cohort. Thus, this study was undertaken to identify the clinicopathological features and survival of patients with clinical N0 or N1 and pathological N2, namely, unsuspected N2.
METHODS: Among 239 patients with pathological N2 NSCLC, we reviewed the cases of 92 (38.5 %) patients who showed unsuspected N2. The prognosis was investigated using the Kaplan-Meier method and a Cox regression model.
RESULTS: The 5-year overall survival (5yOS) of the patients with unsuspected N2 was 51.2 %. Based on a multivariate analysis, age and 18F-fluorodeoxyglucose (FDG) uptake in the lymph nodes were significant prognostic factors of unsuspected N2 (p = 0.0081, 0.0228, respectively). The 5yOS of PET-negative unsuspected N2 (n = 68) was 58.9 %, whereas that of PET-positive unsuspected N2 (n = 24) was 29.7 % (p = 0.0026). Furthermore, the 5yOS of PET-negative unsuspected N2 was significantly better than that of both clinical and pathological N2 s (i.e., suspected N2; n = 60; 5yOS, 42.1 %; p = 0.0051), while no significant difference was observed between PET-positive unsuspected N2 and suspected N2 (p = 0.6325).
CONCLUSIONS: A preoperative evaluation of the lymph nodes by PET/CT has a potential benefit in predicting the prognosis. A thorough evaluation of the lymph nodes is, therefore, needed if the lymph nodes show an FDG uptake, even in cases that show a clinical N0 status on thin section CT scans.

Entities:  

Keywords:  Lung cancer surgery; Mediastinal lymph nodes; Positron emission tomography; Surgical outcomes

Mesh:

Year:  2016        PMID: 27444026     DOI: 10.1007/s00595-016-1372-y

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  23 in total

Review 1.  Optimal imaging protocols for lung cancer staging: CT, PET, MR imaging, and the role of imaging.

Authors:  Narinder S Paul; Sebastian Ley; Ur Metser
Journal:  Radiol Clin North Am       Date:  2012-09       Impact factor: 2.303

2.  Clinical predictors of N2 disease in non-small cell lung cancer.

Authors:  K Takamochi; K Nagai; K Suzuki; J Yoshida; Y Ohde; Y Nishiwaki
Journal:  Chest       Date:  2000-06       Impact factor: 9.410

3.  Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies for clinical stage IA lung adenocarcinoma.

Authors:  Morihito Okada; Haruhiko Nakayama; Sakae Okumura; Hiromitsu Daisaki; Shuji Adachi; Masahiro Yoshimura; Yoshihiro Miyata
Journal:  J Thorac Cardiovasc Surg       Date:  2011-03-25       Impact factor: 5.209

4.  Surgical outcome of stage IIIA- cN2/pN2 non-small-cell lung cancer patients in Japanese lung cancer registry study in 2004.

Authors:  Ichiro Yoshino; Shigetoshi Yoshida; Etsuo Miyaoka; Hisao Asamura; Hiroaki Nomori; Yoshitaka Fujii; Yoichi Nakanishi; Kenji Eguchi; Masaki Mori; Noriyoshi Sawabata; Meinoshin Okumura; Kohei Yokoi
Journal:  J Thorac Oncol       Date:  2012-05       Impact factor: 15.609

5.  Clinical predictors of N2 disease in the setting of a negative computed tomographic scan in patients with lung cancer.

Authors:  K Suzuki; K Nagai; J Yoshida; M Nishimura; K Takahashi; Y Nishiwaki
Journal:  J Thorac Cardiovasc Surg       Date:  1999-03       Impact factor: 5.209

6.  The true false negative rates of esophageal and endobronchial ultrasound in the staging of mediastinal lymph nodes in patients with non-small cell lung cancer.

Authors:  Robert J Cerfolio; Ayesha S Bryant; Mohamad A Eloubeidi; Paul A Frederick; Douglas J Minnich; Kevin C Harbour; Mark T Dransfield
Journal:  Ann Thorac Surg       Date:  2010-08       Impact factor: 4.330

7.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

8.  Is there still a role for mediastinoscopy as the first mediastinal staging procedure in lung cancer?

Authors:  D Waller; K M Skwarski
Journal:  J R Coll Physicians Edinb       Date:  2013

9.  Associations among bronchioloalveolar carcinoma components, positron emission tomographic and computed tomographic findings, and malignant behavior in small lung adenocarcinomas.

Authors:  Morihito Okada; Shunsuke Tauchi; Koichiro Iwanaga; Takeshi Mimura; Yoshitaka Kitamura; Hirokazu Watanabe; Shuji Adachi; Toshiko Sakuma; Chiho Ohbayashi
Journal:  J Thorac Cardiovasc Surg       Date:  2007-06       Impact factor: 5.209

10.  What is the appropriate operative strategy for radiologically solid tumours in subcentimetre lung cancer patients?†.

Authors:  Aritoshi Hattori; Kenji Suzuki; Takeshi Matsunaga; Yoshikazu Miyasaka; Kazuya Takamochi; Shiaki Oh
Journal:  Eur J Cardiothorac Surg       Date:  2014-06-27       Impact factor: 4.191

View more
  2 in total

1.  Oncological outcomes of unsuspected pN2 in patients with non-small-cell lung cancer: a systematic review and meta-analysis.

Authors:  Michiel A IJsseldijk; Richard P G Ten Broek; Bastiaan Wiering; Edo Hekma; Marnix A J de Roos
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-05-10

2.  Differential outcomes of residual disease in surgically-resected non-small cell lung cancer and the importance of guideline-concordant adjuvant therapy.

Authors:  Dustin K Lieu; Li Ding; Elizabeth A David; Sean C Wightman; Scott M Atay; P Michael McFadden; Anthony W Kim
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 3.005

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.